Pharmakon1600-01500247

Base Information

• Chemical Name: Pharmakon1600-01500247
• CAS No.: 20830-75-5
• Molecular Formula: C41H64O14
• Molecular Weight: 780.951
• Hs Code.: 29389090
• NSC Number: 756738
• ChEMBL ID: CHEMBL3039191
• Mol file: 20830-75-5.mol

Synonyms:SR-05000001606;Spectrum_000966;Spectrum2_001262;Spectrum3_000394;Spectrum4_001752;Spectrum5_000604;BSPBio_002207;KBioGR_002224;KBioSS_001446;DivK1c_000867;SPECTRUM1500247;SPBio_001224;CHEMBL3039191;SCHEMBL12841137;HMS502L09;KBio1_000867;KBio2_001446;KBio2_004014;KBio2_006582;KBio3_001427;NINDS_000867;HMS1920G14;HMS2091O04;Pharmakon1600-01500247;CCG-38826;NSC756738;NSC-756738;SDCCGMLS-0066591.P001;IDI1_000867;NCGC00178762-01;NCGC00178762-02;SBI-0052454.P003;AB00052961_02;SR-05000001606-1;SR-05000001606-2;BRD-A94756469-001-02-1;BRD-A94756469-001-03-9

Chemical Property of Pharmakon1600-01500247

Chemical Property:

• Appearance/Colour: White cystalline pwder
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: 248 °C
• Refractive Index: 12 ° (C=10, Pyridine)
• Boiling Point: 931.6 °C at 760 mmHg
• PKA: 13.50±0.70(Predicted)
• Flash Point: 278.5 °C
• PSA: 203.06000
• Density: 1.36 g/cm³
• LogP: 2.21810
• Storage Temp.: Refrigerator
• Solubility.: Soluble in dimethyl sulfoxide and methanol.
• Water Solubility.: 46.08mg/L(room temperature)
• XLogP3: 1.3
• Hydrogen Bond Donor Count: 6
• Hydrogen Bond Acceptor Count: 14
• Rotatable Bond Count: 7
• Exact Mass: 780.42960671
• Heavy Atom Count: 55
• Complexity: 1450

Purity/Quality:

97% ^*data from raw suppliers

Digoxin ≥98%(HPLC) ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Moderately toxic.T, T+
• Hazard Codes: T,T+,F
• Statements: 25-26/27/28-23/25-39/23/24/25-23/24/25-11-28-26
• Safety Statements: 22-36/37/39-45-36/37-16-28A

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
• Isomeric SMILES: C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CCC6C5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
• Description: Digoxin, 3β,14β-dihydroxy-5β-card-20(22)-enolide-3-rigitoxide, is also a glycoside isolated from various types of foxgloves. It differs from digitoxin in that it has an additional hydroxyl group at C16 of the steroid skeleton. It is extracted form the leaves of Digitalis lanta, Digitalis orientalis, or Scrophulariaceae. Digoxin is a cardiac glycoside and metabolite of digitoxin that binds to and inhibits the Na+/K+-ATPase in cardiac tissues in an ATP- and Mg2+-dependent manner. This inhibition results in loss of the transmembrane Na+ gradient, which decreases activity of the Na+/Ca2+ exchanger, increasing intracellular Ca2+ levels, inotropy, and cardiac force. It increases activity of mitochondrial ATPase and actomyosin ATPase in rat hearts, which is directly correlated with increased myofibrillar contractile strength. In vivo, digoxin also decreases right atrial pressure and increases cardiac output in a canine model of congestive heart failure produced by pulmonary artery constriction. Formulations containing digoxin have been used to treat atrial fibrillation.
• Physical properties: Appearance: white crystals or crystalline powder, odorless. Solubility: easily dissolved in pyridine, slightly soluble in dilute alcohol, slightly soluble in chloroform, insoluble in water and ethyl ether. Specific optical rotation: +9.5 to +12.0°. Melting point: 248–250?°C.
• Uses: Digoxin exhibits strong systolic action and slows heart rate. It is removed from the organism faster than digitoxin. It is used from chronic cardiac insufficiency in decompensated valvular disease of the heart, myocardium overload in arterial hypertension, tachycardia, ventricular fibrillation, and other analogous situations. Cardiotonic cardiac stimulant
• Indications: Digoxin is used for congestive heart failure (CHF), paroxysmal supraventricular tachycarelia, atrial fibrillation, and atrial flutter.
• Therapeutic Function: Cardiotonic
• Clinical Use: Supraventricular arrhythmiasSupraventricular arrhythmias
• Drug interactions: Potentially hazardous interactions with other drugsAngiotensin-II antagonists: concentration increased by telmisartanAnti-arrhythmics: concentration increased by amiodarone, dronedarone and propafenone (half maintenance dose of digoxin).Antidepressants: concentration reduced by St John’s wort - avoid.Antifungals: increased toxicity if hypokalaemia occurs with amphotericin; concentration increased by itraconazoleAntimalarials: concentration possibly increased by quinine, hydroxychloroquine and chloroquine; increased risk of bradycardia with mefloquineAntivirals: concentration increased by daclatasvirCalcium-channel blockers: concentration increased by diltiazem, lercanidipine, nicardipine, verapamil and possibly nifedipine; increased risk of AV block and bradycardia with verapamil.Ciclosporin: concentration increased by ciclosporin.Colchicine: possibly increased risk of myopathyDiuretics: increased toxicity if hypokalaemia occurs; concentration increased by spironolactone and possibly potassium canrenoate.Ticagrelor: concentration of digoxin increased

Technology Process of Pharmakon1600-01500247

There total 10 articles about Pharmakon1600-01500247 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 89.7%

Deslanoside (17598-65-1) → digoxin (20830-75-5)

Guidance literature:

With citrate buffer; cyclomaltooctaose; In water; at 45 ℃; for 0.75h; β-D-glucosidase isolated from barley seed;

DOI:10.1016/0008-6215(95)00025-O

Reference yield: 89.7%

Deslanoside (17598-65-1) → digoxin (20830-75-5)

Guidance literature:

With citrate buffer; cyclomaltooctaose; In water; at 45 ℃; for 0.75h; Thermodynamic data; β-D-glucosidase isolated from barley seed; also β-cyclodextrin; E(a); var. temp.;

DOI:10.1016/0008-6215(95)00025-O

Reference yield:

C47H70O17 → digoxin (20830-75-5)

Guidance literature:

With lithium hydroxide; In methanol; water; at 20 ℃; for 3h;

DOI:10.1055/a-1346-5650

upstream raw materials:

beta-Acetyldigoxin

3'''-acetyldigoxin

digitoxin

lanatoside C

Downstream raw materials:

Deslanoside

beta-Acetyldigoxin

3'''-acetyldigoxin

Digoxigenin mono-digitoside

Refernces

• 1、 Lepojevic, Zika,Pekic, Branislav. "Enzymatic transformation of de-O-acetyl-lanatoside C into digoxin". . p. 119 - 124. Retrieved 1995.
• 2、 -. "Fluorescent dyes free of aggregation and serum binding". . . Retrieved 2008/06/13.